APH 1902
Alternative Names: APH-1902Latest Information Update: 28 Dec 2025
At a glance
- Originator Aphios Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Liver-kidney transplant rejection
Most Recent Events
- 28 Dec 2025 No recent reports of development identified for preclinical development in Liver-kidney-transplant-rejection(Prevention) in USA
- 25 Nov 2021 Early research in Liver-kidney transplant rejection (Prevention) in USA (unspecified route) prior to November 2021 (Aphios Corporation pipeline, November 2021)
- 25 Nov 2021 Preclinical trials in Liver-kidney transplant rejection (Prevention) in USA (unspecified route) prior to November 2021 (Aphios Corporation pipeline, November 2021)